Dupilumab Linked to Fewer New Atopic Diagnoses in Children

Key Takeaways

• Among US children with atopic dermatitis, dupilumab initiators had lower observed hazards of a new qualifying atopic diagnosis than matched systemic corticosteroid users across all four age cohorts.
• The largest relative difference in newly recorded atopic diagnoses occurred at ages 2 to 5 years.
• With stricter claims-based confirmation, the association at ages 6 to 11 years was not statistically significant, while associations remained similar in the other three cohorts.

For children with atopic dermatitis, a subsequent diagnosis of food allergy, asthma, allergic rhinitis, or eosinophilic esophagitis raises questions about the course of atopic disease after treatment begins. Whether these conditions are newly recorded after dupilumab initiation rather than systemic corticosteroid use is the comparison of interest across pediatric age groups.

Simpson EL, Paller A, Eichenfield LF, and colleagues conducted a retrospective US claims analysis reported as a conference poster identified as presented at the Fall Clinical Dermatology Conference, October 8–11, 2026, in Las Vegas. Using the Inovalon Insights Real-World Database, they matched 2,897 dupilumab initiators with 2,897 systemic corticosteroid users who had atopic dermatitis. The pediatric cohorts comprised children younger than 2 years and those ages 2 to 5, 6 to 11, and 12 to 17 years. Children with a prior claims-recorded diagnosis of food allergy, asthma, allergic rhinitis, or eosinophilic esophagitis were excluded. The outcome was a newly recorded diagnosis of any of those conditions during follow-up. A sensitivity analysis applied stricter claims-based confirmation of new diagnoses.

In the primary analysis, dupilumab initiators had lower observed hazards of a new qualifying atopic diagnosis than matched systemic corticosteroid users across all four pediatric age cohorts. The largest relative difference occurred among children ages 2 to 5 years: hazard ratio (HR) 0.48 (95% confidence interval [CI], 0.40–0.56). The younger-than-2, 6-to-11, and 12-to-17 cohorts showed the same lower-hazard direction.

With stricter claims-based confirmation of new diagnoses, associations remained similar in three age cohorts. Among children ages 6 to 11 years, however, the association was not statistically significant: HR 0.71 (95% CI, 0.48–1.05). This contrasts with the statistically significant lower hazard for that age group in the primary analysis.

A newly recorded claims diagnosis does not independently establish the biological onset of an allergic disease. The retrospective comparison of matched treatment groups describes an association between treatment initiation and subsequent diagnosis coding, rather than a causal effect. It cannot establish that dupilumab prevents atopic march.

Simpson and colleagues concluded that dupilumab initiation was associated with lower observed atopic march progression than systemic corticosteroid use across the primary pediatric age cohorts, although the association for one cohort was not statistically significant under stricter diagnosis confirmation.

Clinician Questions

Does the dupilumab versus corticosteroid finding apply to children with atopic dermatitis who already have asthma or food allergy?

Children with atopic dermatitis who had previously recorded asthma, food allergy, allergic rhinitis, or eosinophilic esophagitis were excluded from the dupilumab versus systemic corticosteroid comparison. Its findings therefore do not directly establish outcomes for children who already have one of those diagnoses.

Did dupilumab lower the risk of each individual atopic condition in children with atopic dermatitis?

The dupilumab versus systemic corticosteroid comparison in children with atopic dermatitis measured the first newly recorded diagnosis of any of food allergy, asthma, allergic rhinitis, or eosinophilic esophagitis. The findings do not separately establish a reduction for each condition; individual-condition effect estimates were not supplied.

What absolute reduction in new atopic diagnoses was observed with dupilumab in children with atopic dermatitis?

Numerical absolute event risks for dupilumab initiators and matched systemic corticosteroid users with pediatric atopic dermatitis were not supplied, so the relative hazard associations cannot be translated into a stated absolute reduction. Follow-up duration was not specified.

Recommended Reading

• For practical AD therapy escalation: Push Past in AD: Treatment Escalation in Moderate to Severe Atopic Dermatitis—A Regional Workshop Series for Advanced Practice Providers
• For guidance on newer AD therapies: From Disease Assessment to Advanced Therapy: A Practical Framework for Atopic Dermatitis